During the last decade, cell therapies based on CAR-T technology have shown groundbreaking results in R/R hematological malignancies leading to their clinical licensing in acute lymphoblastic leukemia (ALL) and lymphomas, by essentially targeting the B-cell marker CD19 (22). Here, CD19 is linked to acute lymphoblastic leukemia.